×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

US FDA approves Lokelma for hyperkalemia

  1488 Views

eMediNexus    19 May 2018

The US Food and Drug Administration (FDA) has approved sodium zirconium cyclosilicate (Lokelma), a highly-selective, oral potassium-removing agent for adults with hyperkalemia. The drug has been shown to reduce potassium levels in patients with chronic kidney disease, heart failure, diabetes and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.